Matejuk A, Leng Q, Begum M D, Woodle M C, Scaria P, Chou S-T, Mixson A J
Department of Pathology, University of Maryland Baltimore, MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA.
Drugs Future. 2010 Mar;35(3):197. doi: 10.1358/dof.2010.035.03.1452077.
Acquired drug resistance to mycotic infections is rapidly emerging as a major medical problem. Opportunistic fungal infections create therapeutic challenges, particularly in high risk immunocompromised patients with AIDS, cancer, and those undergoing transplantation. Higher mortality and/or morbidity rates due to invasive mycosis have been increasing over the last 20 years, and in light of growing resistance to commonly used antibiotics, novel antifungal drugs and approaches are required. Currently there is considerable interest in antifungal peptides that are ubiquitous in plant and animal kingdoms. These small cationic peptides may have specific targets or may be multifunctional in their mechanism of action. On the basis of recent advances in protein engineering and solid phase syntheses, the utility and potential of selected peptides as efficient antifungal drugs with acceptable toxicity profiles are being realized. This review will discuss recent advances in peptide therapy for opportunistic fungal infections.
获得性真菌感染耐药性正迅速成为一个主要的医学问题。机会性真菌感染带来了治疗挑战，尤其是在患有艾滋病、癌症的高风险免疫功能低下患者以及接受移植的患者中。在过去20年里，侵袭性真菌病导致的死亡率和/或发病率不断上升，鉴于对常用抗生素的耐药性不断增加，需要新型抗真菌药物和方法。目前，动植物界普遍存在的抗真菌肽引起了人们的极大兴趣。这些小的阳离子肽可能有特定的靶点，或者其作用机制可能是多功能的。基于蛋白质工程和固相合成的最新进展，选定的肽作为具有可接受毒性特征的高效抗真菌药物的效用和潜力正在得到实现。本综述将讨论机会性真菌感染肽疗法的最新进展。
